PledPharma Release: New Study Shows Superior Ability of PledOx to Reduce Chemotherapy Side Effects
12/27/2012 9:07:23 AM
Stockholm, 2012-12-27 12:16 CET (GLOBE NEWSWIRE) -- Colorectal cancer is the third most common cancer-related cause of death in the Western world. A standard treatment in this disease is oxaliplatin-based chemotherapy. However, serious side effects in more than half of the patients lead to an intolerable burden and cause dose reductions, delays, or, in worst-case scenarios, complete discontinuation of the therapy. Chemotherapy exerts negative effects on blood-forming bone marrow, which often leads to severe shortage of white blood cells. The Swedish specialty pharmaceutical company PledPharma is developing PledOx as a chemotherapy adjunct to reduce severe and dose-limiting side effects.